News
VXRT
--
0.00%
--
4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts
Zacks · 2h ago
Analysts Pound the Table on This Strong Buy Cannabis Stock
A journey of a thousand miles begins with a single step, and a big one in this case. Last week, COVID vaccine researcher Vaxart (VXRT) reported preclininal study results suggesting ingestion of its oral coronavirus vaccine VXA-CoV2-1 helped to reduce viral loads in lab hamsters. Indeed, according to Vaxart, the new vaccine appeared to provoke "a broader immune response that has the potential to offer superior protection against SARS-CoV-2," than comparable injectable vaccines. Moreover, because oral vaccinations are obviously less stressful for patients (show me a patient who prefers needles to pills, if you disagree), investors logically took the study results -- preliminary as they are -- as a good sign for Vaxart stock. Among the fans are analysts Kumaraguru Raja at Brookline Capital Markets and Mayank Mamtani at B. Riley Securities, who sing Vaxart's praises in the wake of the company's VXA-CoV2-1 news. What made them so optimistic? Brookline's Raja notes that Vaxart's news resulted from a "Hamster Challenge" study preparatory to Phase 1 clinical trials. Vaxart says that enrollment of patients to begin those Phase 1 trials has already completed, however, and Raja predicts that investors will be treated to "positive initial data before year end" -- a potential catalyst that could drive up the stock price long before Vaxart has a chance to report any more earnings (or losses) news. That right there sounds propitious for a start.Moving all the way through Phase 3 trials (assuming the vaccine gets that far) could still take the entirety of next year, with distribution beginning no sooner than early 2022. On the one hand, that means Vaxart is going to be getting a pretty late start relative to all the other vaccines coming to market. However, on the other hand, Raja also points out that in a crowded field in which every second biotech on the planet seems to have a Covid vaccine in the works, "Vaxart’s COVID-19 vaccine could potentially be the first oral vaccine" (emphasis added), which would certainly set the stock apart from its peers.Additionally, Raja notes (and Mamtani agrees) that because Vaxart's vaccine comes in pill form, it "will not require cold chain for storage and delivery on account of being stable tablets that have long life at room temperature." This advantage, lacking in most injectable vaccines, says Mamtani, holds the potential to turn Vaxart into "a key player in the second wave of C-19 vaccine candidates."To this end, both analysts rate Vaxart stock a "buy" with Raja suggesting a $20 price target on the $5 stock, and Mamtani saying Vaxart stock could go as high as $22. (See Vaxart stock analysis on TipRanks)To find good ideas for cannabis stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.
TipRanks · 11/16 23:01
Coronavirus Vaccine-Test News Roundup: Moderna, Inovio, J&J
At least 10 coronavirus-vaccine candidates are in late-stage studies, according to the Regulatory Affairs Professionals Society.
TheStreet.com · 11/16 16:55
Vaxart Hosting Key Opinion Leader Panel Call for Investors
Title: An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus Key topics: COVID-19: Immunity & Immunological Memory Norovirus: Disease Burden & Prevention. The Current Status of Vaccine Development Mucosal Immunity and the importance of secretory IgA Administration and Logistical Advantages of a PillInvestor Panel Being Held on Thursday, November 19th @ 12pm Eastern TimeSOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that it will host a Key Opinion Leader (KOL) panel for investors entitled “An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus?” on Thursday, November 19, 2020 at 12pm Eastern Time.These KOLs will provide their perspectives on the COVID-19 and Norovirus disease landscapes, highlighting the tracking of immune responses post-infection, and on preventing infection and disease spread. Vaxart's management team will also provide an update on its first-in-class oral tablet vaccine platform as well as Vaxart’s Phase 1 trial for Norovirus and results from preclinical studies on Vaxart’s investigational COVID-19 vaccine.Event Agenda: * Dr. Pepper on the importance of immunological memory and quick responses to a pathogen, and how it relates to COVID-19. * Dr. Vinjé to speak on Norovirus incidence, outbreak surveillance, and global vaccine developments to date. * Dr. Sean Tucker, Ph.D. (Vaxart) to discuss VXA-CoV2-1, Vaxart’s oral investigational tablet COVID-19 vaccine. What the pre-clinical data show and what’s next. He will also discuss Vaxart’s Norovirus oral vaccine program.Both KOLs and the Vaxart management team will be available for Q&A following the formal presentation.To register for the call, please click here.Marion Pepper, Ph.D. is an internationally recognized immunologist. She is an Associate Professor in the Department of Immunology at the University of Washington School of Medicine. Her research focuses on how protection from disease, known as immunity, develops. Specifically, her lab strives to understand how specialized immune cells, called T cells and B cells, respond to various types of infection or allergic inflammation in an effort to make better vaccines and therapeutics. Her published work has been cited over 4,000 times, and she is on the editorial board of several top tier journals, including Cell Reports and Immunity. She has served as a scientific consultant for multiple for profit companies focused on immunotherapeutics and is a member of the scientific advisory board of Neoleukin Therapeutics. Dr. Pepper has presented her work at over 70 national and international universities and conferences. In 2017, she was named a recipient of the prestigious Buroughs Wellcome Fund Investigators in the Pathogenesis of Infectious Disease Award. In addition to her research, she is also passionate about communicating science to others and teaches undergraduate, medical school and graduate level courses. She is a strong advocate for women in science, and recently contributed an essay to Nature Immunology on the topic.Jan Vinjé, Ph.D., is head of the National Calicivirus Laboratory and Director of CaliciNet in the Division of Viral Diseases at the Centers for Disease Control and Prevention (CDC) in Atlanta, GA. Dr. Vinjé received his Ph.D. at the University of Utrecht, the Netherlands, in 1999. After completing a postdoctoral fellowship and an appointment as research assistant professor at the University of North Carolina in Chapel Hill, he joined CDC in 2006. Over the past 10 years, he has served on program advisory committees from several European research projects (FP6, FP7). He has served as technical expert on the norovirus subcommittee of the National Advisory Committee on Microbiological Criteria for Foods and is the chair of the International Committee on Taxonomy of Viruses study groups on Caliciviridae. He is currently a member of the editorial board of the Journal of Clinical Microbiology and associate editor of the journal Food and Environmental Virology, and he serves as an ad hoc reviewer for multiple high-impact journals. Dr. Vinjé has published over 200 peer-reviewed publications and several book chapters. His research interests include all aspects of viral gastrointestinal disease, including detection, characterization, and prevention and control of norovirus infections.About VaxartVaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and have the potential to provide sterilizing immunity for diseases such as COVID-19. Vaxart believes that a room temperature stable tablet is easier to distribute, store and administer than injectable vaccines and may provide a significantly faster response to a pandemic than injectable vaccines, enabling a greater portion of the population to be protected. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). For more information, please visit www.vaxart.com.Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from pre-clinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “plan” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates, and preclinical and clinical results and trial data (including plans with respect to the COVID-19 vaccine product candidates); expectations relating to Vaxart’s relationship with Emergent, KindredBio and AMS including their ability to produce bulk cGMP vaccines and the timing thereof; and Vaxart’s expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for mucosal pathogens such as norovirus, flu and RSV, as well as coronaviruses such as SARS, MERS and SARS-CoV-2. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners control, including the recent outbreak of COVID-19; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Operation Warp Speed may not result in a positive financial impact on Vaxart’s financial results that Vaxart may not be able to obtain, maintain and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to resolve pending legal matters; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.Contacts:  Media RelationsInvestor Relations Gloria Gasaatura LifeSci Communications Tel: (646) 970-4688 ggasaatura@lifescicomms.comDavid R. Holmes LifeSci Advisors, LLC Tel: (646) 970-4995 dholmes@lifesciadvisors.com
GlobeNewswire · 11/16 13:30
Vaxart Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today that management will be participating in two upcoming virtual investor conferences and invites investors to participate by webcast. Please see additional details below: * Jefferies 2020 Virtual London Healthcare Conference, November 17-19, 2020 Management will deliver a company presentation on Thursday, November 19th at 2:20 p.m. ET and will also be available for one-on-one meetings. A live and archived webcast of the presentation will be available on the Investors section of the Vaxart website: https://investors.vaxart.com/events-presentations * Piper Sandler 32nd Annual Virtual Healthcare Conference, December 1-3, 2020  Management will present in a fireside chat format and will be available for one-on-one meetings. The presentations will be available prior to the dates of the conference. A replay of the fireside chat will be available in the Investors section of the Vaxart website: https://investors.vaxart.com/events-presentationsAbout VaxartVaxart is a clinical-stage biotechnology company focused on developing oral tablet vaccines designed to generate mucosal and systemic immune responses that protect against a wide range of infectious diseases and have the potential to provide sterilizing immunity for diseases such as COVID-19. Vaxart believes that a room temperature stable tablet is easier to distribute, store and administer than injectable vaccines and may provide a significantly faster response to a pandemic than injectable vaccines, enabling a greater portion of the population to be protected. Vaxart’s development programs include oral tablet vaccines that are designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). For more information, please visit www.vaxart.com.Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from pre-clinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “plan” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop and commercialize its product candidates, and preclinical and clinical results and trial data (including plans with respect to the COVID-19 vaccine product candidates); expectations relating to Vaxart’s relationship with Emergent, KindredBio and AMS including their ability to produce bulk cGMP vaccines and the timing thereof; and Vaxart’s expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for mucosal pathogens such as norovirus, flu and RSV, as well as coronaviruses such as SARS, MERS and SARS-CoV-2. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners control, including the recent outbreak of COVID-19; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Operation Warp Speed may not result in a positive financial impact on Vaxart’s financial results that Vaxart may not be able to obtain, maintain and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to resolve pending legal matters; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.Contacts:  Media RelationsInvestor Relations Gloria Gasaatura LifeSci Communications Tel: (646) 970-4688 ggasaatura@lifescicomms.comDavid R. Holmes LifeSci Advisors, LLC Tel: (646) 970-4995 dholmes@lifesciadvisors.com
GlobeNewswire · 11/16 12:00
Vaxart EPS beats by $0.01, misses on revenue
Vaxart (VXRT): Q3 GAAP EPS of -$0.08 beats by $0.01.Revenue of $0.27M (-40.0% Y/Y) misses by $0.8M.Shares -4%.Press Release
Seekingalpha · 11/12 21:34
Vaxart Q3 EPS $(0.08) Up From $(0.32) YoY, Sales $265.00K Down From $454.00K YoY
Vaxart (NASDAQ:VXRT) reported quarterly losses of $(0.08) per share. This is a 75 percent increase over losses of $(0.32) per share from the same period last year. The company reported $265.00 thousand in sales this
Benzinga · 11/12 21:03
Mid-Day Market Update: Nasdaq Turns Lower; EuroDry Shares Jump After Q3 Results
Midway through trading Thursday, the Dow traded down 0.53% to 29,241.99 while the NASDAQ fell 0.19% to 11,763.76. The S&P also fell, dropping 0.50% to 3,554.65.
Benzinga · 11/12 17:25
Akers Biosciences, Cidara Therapeutics leads healthcare gainers; Applied Therapeutics, Soliton among major losers
Gainers: Akers Biosciences (AKER) +45%, Cidara Therapeutics (CDTX) +29%, Five Prime Therapeutics (FPRX) +24%, Zhongchao (ZCMD) +22%, Vaxart (VXRT) +22%.Losers: Applied Therapeutics (APLT) -12%, Soliton (SOLY) -13%, Harmony Biosciences Holdings (HRMY) -10%, Can-Fite BioPharma (CANF) -10%, Oncternal Therapeutics (ONCT) -9%.
Seekingalpha · 11/12 16:04
Vaxart Shares Jump on Promising Data for Its COVID-19 Vaccine
The biotech says its room-temperature-stable oral tablet vaccine would a more practical solution to the coronavirus pandemic.
TheStreet.com · 11/12 15:03
Vaxart COVID-19 vaccine shows encouraging action in animal study
Vaxart (VXRT) jumps 20% in premarket, in reaction to additional data from a preclinical study evaluating its COVID-19 vaccine candidate.Results showed a significant 4-5 log (10, 000x - 100,000x) reduction in lung
Seekingalpha · 11/12 13:38
Vaxart's COVID-19 vaccine candidate shows benefit in preclinical studies
Vaxart (VXRT) jumps 20% in premarket, in reaction to additional data from preclinical study evaluating its COVID-19 vaccine candidate.Data showed significant reduction in lung viral load of 4-5 logs in hamsters that
Seekingalpha · 11/12 13:38
GRWG, PDD, RUN and XPEV among premarket gainers
EuroDry (EDRY) +127% on Q3 results.Zhongchao (ZCMD) +67% on cooperation agreement with Takeda Pharmaceutical.Sino-Global Shipping America (SINO) +50%.Fossil Group (FOSL) +25% on Q3 results.Pinduoduo (PDD) +23% on Q3 results.Five Prime Therapeutics (FPRX) +21% as anti-CCR8 antibody FPA157 shows promising effect.Euroseas (ESEA)
Seekingalpha · 11/12 13:26
Vaxart Announces Additional Data From Hamster Challenge Study Of Its Oral COVID-19 Vaccine; Says Saw 'Robust Immune Response and Significantly Reduce Viral Load'
Robust Immune Response and Significantly Reduce Viral Load SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ:VXRT), a clinical-stage biotechnology company developing oral vaccines
Benzinga · 11/12 13:02
Vaxart Announces Additional Data from Hamster Challenge Study of its Oral COVID-19 Vaccine
Robust Immune Response and Significantly Reduce Viral LoadSOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, announced today additional results from its Hamster Challenge Study: * Significant reduction in lung viral load of 4-5 logs in hamsters that received two oral vaccine doses, as compared to non-vaccinated animals. * Potent induction of antibody response, with serum IgG antibody titers above 10,000 in hamsters that received two oral vaccine doses. * Oral vaccination protected as well as intranasal vaccination against intranasal challenge with respect to key indicators: protection from weight loss, protection from increase in lung weight, viral load reduction, and induction of serum IgG antibodies, demonstrating that mucosal protection by both routes of administration was comparable. As previously announced, all hamsters that received two oral doses of Vaxart’s COVID-19 vaccine candidate showed no systemic weight loss, a key indicator of protection against COVID-19 in this animal model. By contrast, the unvaccinated animals lost approximately 9% total weight. Additionally, unvaccinated hamsters had over two times (2x) the relative lung weight of orally vaccinated hamsters, a sensitive indicator of serious disease that correlates with the viral load findings.“These additional data provide further evidence supporting the efficacy potential of our oral COVID-19 vaccine candidate,” said Andrei Floroiu, chief executive officer of Vaxart. “In addition, we believe that our room-temperature-stable oral tablet vaccine would be a more convenient, more practical solution to the COVID-19 pandemic as compared to cold-chain dependent injectable vaccines.”The study evaluated Vaxart’s recombinant adenoviral vaccine, with doses administered at 0 and 4 weeks. Animals were challenged with SARS-CoV-2 at week 8. Hamsters are considered an excellent model for assessing COVID-19 infection since they can be infected via the intranasal route, and, if infected, they demonstrate clinical symptoms such as weight loss, labored breathing and ruffled fur. Furthermore, hamsters also develop lung issues similar to those seen in humans. Images of hamsters infected with SARS-CoV-2 reveal severe lung injury comparable to what has been observed in infected human lungs, including severe, multi-lobular ground glass opacity, and regions of lung inflammation.About VaxartVaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart has believes that its proprietary tablet vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Its development programs currently include tablet vaccines designed to protect against coronavirus, norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immuno-oncology indication. Vaxart has filed broad domestic and international patents covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “plan” and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to develop (including enrolling a sufficient number of subjects and manufacturing sufficient quantities of its product candidates) and commercialize its COVID-19 vaccine candidate and preclinical or clinical results and trial data (including plans with respect to the COVID-19 vaccine product candidates); expectations regarding the timing and nature of future announcements including, those related to clinical trials and results of preclinical studies; Vaxart’s expectations with respect to the important advantages it believes its oral vaccine platform can offer over injectable alternatives, particularly for coronaviruses; the potential applicability of results seen in our preclinical studies or trials to those that may be seen in human studies or clinical trials; the expected role of mucosal immunity in blocking transmission of COVID-19; and Vaxart’s expectations with respect to the effectiveness of its products or product candidates, including Vaxart’s potential role in mitigating the impact of COVID-19 globally. Vaxart may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials or preclinical studies, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial and preclinical study data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners’ control, including the recent outbreak of COVID-19; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the “Risk Factors” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.Contacts:     Media RelationsInvestor Relations    Gloria Gasaatura David R. Holmes LifeSci CommunicationsLifeSci Advisors, LLC Tel: (646) 970-4688Tel: (646) 970-4995 ggasaatura@lifescicomms.comdholmes@lifesciadvisors.com
GlobeNewswire · 11/12 13:00
ACB, VXRT, AHT and GNFT among midday movers
Gainers: Five Prime Therapeutics (FPRX) +259%.Fuel Tech (FTEK) +96%.Equillium (EQ) +61%.Immuron (IMRN) +29%.Genfit (GNFT) +27%.Performance Shipping (PSHG) +25%.Revlon (REV) +21%.Eastside Distilling (EAST) +20%.Vaxart (VXRT) +20%.Myomo (MYO) +19%.Losers: eGain (EGAN) -29%.Summit Wireless Technologies (WISA) -21%.Ashford Hospitality
Seekingalpha · 11/11 17:42
If You Had Bought Vaxart (NASDAQ:VXRT) Stock A Year Ago, You Could Pocket A 910% Gain Today
Some Vaxart, Inc. (NASDAQ:VXRT) shareholders are probably rather concerned to see the share price fall 67% over the...
Simply Wall St. · 11/10 19:56
Second tier COVID-19 vaccine developers under pressure on positive Pfizer/BioNTech data
Pfizer and BioNTech's announcement that, based on preliminary data, their COVID-19 vaccine is 90% effective and an emergency use authorization ((EUA)) is only weeks away has led to downward pressure
Seekingalpha · 11/09 15:14
CureVac: Overvalued But Can Pop Again
It was a booming start for CureVac during its IPO in August with the stock popping by 250%.There have been some recent news concerning safety of the vaccine candidate.Market contenders are either ahead or behind the German biotech when considering the state of the clinical trials.Considering fundamentals based on the EV/Sales metric, CureVac is overvalued.Still, this is a biotech operating in a niche market and momentum-induced news could make it pop again.
Seekingalpha · 11/06 17:26
Sorrento: Why I Am Skeptical About Its Covid-19 Pipeline
Sorrento currently presents a wide multitude of candidate drugs to combat COVID-19.Due to this huge Covid-19 program, the share price has skyrocketed in recent months, although since the August peak the stock price has been deflating to reach around $7.The problem here is that the company has over-reported the supposed "incredible results" in the preclinical tests obtained for some of these candidate drugs.Unless robust and reliable trial results in Covid-19 patients are reported soon, I expect a downward trend over the next several weeks and months.
Seekingalpha · 11/03 14:21
Webull provides a variety of real-time VXRT stock news. You can receive the latest news about VAXART through multiple platforms. This information may help you make smarter investment decisions.
About VXRT
Vaxart, Inc., formerly Aviragen Therapeutics, Inc., is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally. The Company has three product candidates in clinical development that address viral infections that have limited therapeutic options. Its products include vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics in Phase IIb SPIRITUS trial; BTA585, an oral fusion (F) protein inhibitor in Phase II development for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in Phase II development for condyloma caused by human papillomavirus Types 6 and 11. It has preclinical RSV non-fusion inhibitor program. It has focused its research and drug development capabilities on discovering and developing small molecule compounds that can prevent or treat infectious diseases.
More